2023-03-21 17:46 |
153SM-FAPI-46 RADIOLIGAND THERAPY WITH HIGH-MOLAR ACTIVITY 153SM
/ Prior, John (CHUV) ; Kratochwill, Clemens (Heidelberg University Hospital) ; Ooms, Marteen (SCK CEN) ; Cocolios, Thomas Elias (KU Leuven (BE)) ; Decristoforo, Clemens (INMUL)
New radiobioconjugates targeting fibroblast overexpressed in certain forms of cancers have recently been developed by the dept of nuclear medicine in Heidelberg and have shown important results in a range of different preclinical and clinical investigations. It demonstrates the potential of a new generation of radiopharmaceuticals targeting the Fibroblast Activation Protein (FAP), quinolone-based FAP inhibitors (FAPI) with a DOTA-chelator moiety and have shown potential benefits in both diagnosis and treatment, including patients presenting disseminated metastasis in lungs. [...]
MED-035.-
Geneva : CERN, 2023 - 3.
Fulltext: DOC;
|
Detaljert visning - Lignende elementer
|
2023-03-21 17:40 |
Determination of 227Ac impurity in 225Ac using alpha spectrometry
/ Cusnir, Ruslan (Centre Hospitalier Universitaire Lausanne CHUV (CH)) ; Bailat, Claude (CHUV) ; Straub, Marietta (Centre Hospitalier Universitaire Lausanne CHUV (CH))
225 Ac (actinium-225, t 1/2 = 9.9 days) is currently in the spotlight owing to its promising radiotherapeutic applications in nuclear medicine. This alpha-emitter can be produced using an accelerator, however this route involves the formation of an undesirable radionuclidic impurity of 227 Ac (actinium-227, t 1/2 = 21.8 years). [...]
MED-034.-
Geneva : CERN, 2023 - 2.
Fulltext: PDF;
|
Detaljert visning - Lignende elementer
|
2023-03-17 15:06 |
Detaljert visning - Lignende elementer
|
2021-11-07 23:57 |
PRISMAP – The European medical radionuclide programme: CERN-MEDICIS contribution
/ Stora, Thierry (CERN)
PRISMAP is the European medical radionuclide programme on the production of high purity radionuclides (radioactive isotopes) by mass separation (www.prismap.eu). We federate a European consortium of the key intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical and healthcare research institutes in the active translation of the emerging radionuclides into medical diagnosis and treatment. [...]
MED-032.-
Geneva : CERN, 2021 - 2.
Fulltext: DOC;
|
Detaljert visning - Lignende elementer
|
2021-03-01 19:20 |
Theranostics studies using 152/149Tb-labeled anti-CXCR4 probes in tumor mice
/ Cleeren, Frederik (KU Leuven)
The chemokine receptor CXCR4 is a seven transmembrane G protein-coupled receptor and is involved in various inflammatory and autoimmune diseases, as well as in cancer metastasis and progression. Binding of the endogenous ligand CXCL12 (also known as stromal cell-derived factor-1α (SDF-1α)) to CXCR4 leads to activation of downstream signaling pathways that exert critical functions in development (organogenesis), normal physiology as well in disease processes. [...]
MED-031.-
Geneva : CERN, 2021 - 4.
Fulltext: PDF;
|
Detaljert visning - Lignende elementer
|
2021-03-01 19:08 |
Detaljert visning - Lignende elementer
|
2021-02-26 09:23 |
Detaljert visning - Lignende elementer
|
2021-02-26 09:17 |
Detaljert visning - Lignende elementer
|
2020-09-14 19:12 |
Strengthening theranostics or radionuclide therapy in Pakistan
/ Khan, Irfan Ullah (INMOL Institute of Nuclear Medicine and Oncology)
In this project, we are interested to strengthen theranostics or radionuclide therapy in Pakistan. Due to its ability of targeting only cancerous cells, the field of theranostics is rapidly emerging worldwide and in developed countries, it is considered as real cancer diagnosis and treatment modality. [...]
MED-027.-
Geneva : CERN, 2020 - 6.
Fulltext: DOCX;
|
Detaljert visning - Lignende elementer
|
2020-09-14 15:50 |
Facilities and Expertise in nuclear medicine
/ Khan, Irfan Ullah (INMOL Institute of Nuclear Medicine and Oncology)
This technical note is submitted following the accession of Pakistan to the MEDICIS collaboration as endorsed at the 5th Board, and required as follow-up..
MED-026.-
Geneva : CERN, 2020 - 2.
clinical qualification for radioisotopes: DOC;
|
Detaljert visning - Lignende elementer
|
|
|